Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A   Lamos Elizabeth M   Davis Stephen N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

By He Y.-L.   Sabo R.   Campestrini J.   Wang Y.   Ligueros-Saylan M.   Lasseter K.   Dilzer S.   Howard D.   Dole W.  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 7, 2007-07 ,pp. : 677-686

Springer Publishing Company

Access to resources Recommend Favorite

Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor

By  

Current Drug Targets, Vol. 13, Iss. 7, 2012-06 ,pp. : 970-983

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety

By  

Current Medicinal Chemistry, Vol. 18, Iss. 31, 2011-11 ,pp. : 4753-4760

Bentham Science Publishers

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki   Abe Masanori   Higuchi Terumi   Mizuno Mari   Suzuki Hiroko   Matsumoto Shiro   Ito Midori   Maruyama Noriaki   Okada Kazuyoshi   Soma Masayoshi  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite